Cover Image
市場調查報告書

Rottapharm SpA :產品平台分析

Rottapharm SpA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 199790
出版日期 內容資訊 英文 44 Pages
訂單完成後即時交付
價格
Back to Top
Rottapharm SpA :產品平台分析 Rottapharm SpA - Product Pipeline Review - 2015
出版日期: 2015年09月16日 內容資訊: 英文 44 Pages
簡介

Rottapharm SpA 是開發並提供醫藥品,營養供給食品,個人保健產品的一般成藥廠商。該公司產品主要有心臟,胃,婦產科,風濕性,泌尿器官系統,呼吸系統等疾病的治療藥。

本報告提供Rottapharm SpA 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,以及最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Rottapharm SpA的基本資料

Rottapharm SpA概要

  • 主要資訊
  • 企業資料

Rottapharm SpA:R&D概要

  • 主要的治療範圍

Rottapharm SpA:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Rottapharm SpA:開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Rottapharm SpA:藥物簡介

  • andolast
  • dexloxiglumide
  • CR-3294
  • CR-4056
  • itriglumide
  • neboglamine
  • CR-6086
  • CRB-0016
  • CRB-0017
  • CRB-0089
  • BRU-8392
  • CR-4174 Series
  • CR-4892 Series
  • CR-5259 Series
  • CR-5542 Series
  • CR-5772 Series
  • CR-5790 Series
  • CR-8357
  • CRB-0022
  • VA-964

Rottapharm SpA:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Rottapharm SpA:最近的開發平台趨勢

Rottapharm SpA:暫停中的計劃

Rottapharm SpA:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • dexloxiglumide

Rottapharm SpA:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07575CDB

Summary

Global Markets Direct's, 'Rottapharm SpA - Product Pipeline Review - 2015', provides an overview of the Rottapharm SpA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Rottapharm SpA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Rottapharm SpA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Rottapharm SpA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Rottapharm SpA's pipeline products

Reasons to buy

  • Evaluate Rottapharm SpA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Rottapharm SpA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Rottapharm SpA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Rottapharm SpA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Rottapharm SpA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Rottapharm SpA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Rottapharm SpA Snapshot
    • Rottapharm SpA Overview
    • Key Information
    • Key Facts
  • Rottapharm SpA - Research and Development Overview
    • Key Therapeutic Areas
  • Rottapharm SpA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Rottapharm SpA - Pipeline Products Glance
    • Rottapharm SpA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Rottapharm SpA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Rottapharm SpA - Drug Profiles
    • CR-4056
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dexloxiglumide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • itriglumide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-6086
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CRB-0016
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CRB-0017
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CRB-0089
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BRU-8392
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-4174 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-4892 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-5259 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-5542 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-5790 Series
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CR-8357
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CRB-0022
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VA-964
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Rottapharm SpA - Pipeline Analysis
    • Rottapharm SpA - Pipeline Products by Target
    • Rottapharm SpA - Pipeline Products by Route of Administration
    • Rottapharm SpA - Pipeline Products by Molecule Type
    • Rottapharm SpA - Pipeline Products by Mechanism of Action
  • Rottapharm SpA - Recent Pipeline Updates
  • Rottapharm SpA - Dormant Projects
  • Rottapharm SpA - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Rottapharm SpA, Key Information
  • Rottapharm SpA, Key Facts
  • Rottapharm SpA - Pipeline by Indication, 2015
  • Rottapharm SpA - Pipeline by Stage of Development, 2015
  • Rottapharm SpA - Monotherapy Products in Pipeline, 2015
  • Rottapharm SpA - Phase II, 2015
  • Rottapharm SpA - Preclinical, 2015
  • Rottapharm SpA - Discovery, 2015
  • Rottapharm SpA - Pipeline by Target, 2015
  • Rottapharm SpA - Pipeline by Route of Administration, 2015
  • Rottapharm SpA - Pipeline by Molecule Type, 2015
  • Rottapharm SpA - Pipeline Products by Mechanism of Action, 2015
  • Rottapharm SpA - Recent Pipeline Updates, 2015
  • Rottapharm SpA - Dormant Developmental Projects,2015
  • Rottapharm SpA, Other Locations
  • Rottapharm SpA, Subsidiaries

List of Figures

  • Rottapharm SpA - Pipeline by Top 10 Indication, 2015
  • Rottapharm SpA - Pipeline by Stage of Development, 2015
  • Rottapharm SpA - Monotherapy Products in Pipeline, 2015
  • Rottapharm SpA - Pipeline by Top 10 Target, 2015
  • Rottapharm SpA - Pipeline by Top 10 Molecule Type, 2015
  • Rottapharm SpA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top